Intrinsiqq
Elanco Animal Health Incorporated logo

Elanco Animal Health Incorporated Financials

ELAN

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 11 available years
Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue$5,020$4,715$4,439$4,417$4,411$4,764
Cost of Revenue$2,241$2,122$2,003$1,931$1,913$2,132
Gross Profit$2,779$2,593$2,436$2,486$2,498$2,632
General & Administrative$1,519$1,430$1,314$1,285$1,265$1,403
Research & Development$371$368$344$327$321$369
Other Operating Expenses$1-$19-$18-$75-$32–
Total Operating Expenses$4,131$3,920$3,951$5,612$4,483$5,335
Operating Income$889$795$488-$1,195-$72-$571
Non-Operating
Net Interest Expense-$248-$177-$204-$273-$241-$236
Other Non-Operating Income (Expense)-$807-$842$204$273$241$236
EBT (Earnings Before Tax)-$166-$224$488-$1,195-$72-$571
Income Tax Expense$33$8$150$36$6-$88
Net Income
Net Income-$199-$232$338-$1,231-$78-$483
Per Share Data
Revenue Per Share$9.92$9.50$8.93$8.97$9.03$9.78
EPS (Basic)-$0.41-$0.47$0.68-$2.50-$0.16-$0.99
EPS (Diluted)-$0.40-$0.47$0.68-$2.50-$0.16-$0.99
Weighted Avg Shares (Basic)499.5M496.4M494.0M492.3M488.3M487.2M
Weighted Avg Shares (Diluted)505.9M496.4M497.3M492.3M488.3M487.2M
Shares Outstanding505.9M496.4M497.3M492.3M488.3M487.2M

Elanco Animal Health (ELAN) financials: revenue, profit and margins

Elanco Animal Health (ELAN) generated about $5.0 billion in revenue and -$199 million in net income (a -4.0% net margin) over the trailing twelve months, growing at roughly 7.6% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Elanco Animal Health's (ELAN) revenue?+

Elanco Animal Health generated about $5.0 billion in revenue over the trailing twelve months. Revenue has grown at roughly 7.6% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Elanco Animal Health profitable?+

Elanco Animal Health reported about -$199 million in net loss over the trailing twelve months, a net margin of roughly -4.0%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Elanco Animal Health's profit margins?+

Elanco Animal Health runs a gross margin of about 55.4%, an operating margin of about 17.7%, a net margin of about -4.0%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Elanco Animal Health growing?+

Elanco Animal Health's revenue has compounded at roughly 7.6% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside ELAN's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 3 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 19 Sept 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ELAN

CompareIntrinsic value
JAZZJazz Pharmaceuticals plc
$234.66+2.14%58
ONCBeOne Medicines Ltd.
$377.78+6.42%65
PRGOPerrigo Company plc
$15.83+0.83%17
OGNOrganon & Co.
$13.83-0.14%28
ALNYAlnylam Pharmaceuticals Inc
$161.08+0.74%81
BMRNBiomarin Pharmaceutical Inc.
$57.13+2.64%47
UTHRUnited Therapeutics Corporation
$608.49+1.19%78
AMRXAmneal Pharmaceuticals Inc.
$19.95-1.29%57

Held by ETFs

ELAN is in 140 US ETFs. The largest of them, with ELAN's weight in each:

Spot a number that looks wrong? Check it in ELAN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ELAN

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.